Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / SciBase enrolls first patient in DETECT-AD
Tech medical study

SciBase enrolls first patient in DETECT-AD

Analysis based on 7 articles · First reported Jun 10, 2026 · Last updated Jun 10, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The announcement of the first patient enrollment in the DETECT-AD study by SciBase, in collaboration with Altor BioScience, is likely to generate positive market sentiment for both companies. This development could lead to increased investor interest in SciBase, particularly if the study proves successful in predicting Atopic Dermatitis flares, potentially enhancing its Nevisense platform's market value and adoption.

Biotechnology Healthcare
Event Summary

SciBase Holding AB, a medical technology company, announced the enrollment of the first patient in its new multicenter prospective clinical study, DETECT-AD. This study, conducted in collaboration with Altor BioScience, aims to assess the ability of SciBase's Electrical Impedance Spectroscopy (EIS) method to predict the onset of flares in patients with Atopic Dermatitis. The goal is to enable proactive interventions, improve patient quality of life, and reduce the burden of unpredictable flare-ups in this chronic inflammatory skin condition. Pia Renaudin, CEO of SciBase, highlighted the significance of this milestone in transforming Atopic Dermatitis management. SciBase's Nevisense platform, which combines AI and advanced EIS technology, is built on over 20 years of research from the Karolinska Institute in Sweden.

Key Actions
100 SciBase announced patient enrollment
70 SciBase developed Nevisense platform
70 Altor BioScience collaborated on study SciBase
Entities Involved
stock
SciBase
SciBase announced the enrollment of the first patient in a new study, DETECT-AD, to assess flare prediction in Atopic Dermatitis, which could enhance its Nevisense platform and market position.
Importance 100 Sentiment 50
priv
Altor BioScience
Altor BioScience is collaborating with SciBase on the DETECT-AD study, which is the first study through their partnership, potentially benefiting its research and development efforts.
Importance 70 Sentiment 30
per
Pia Renaudin
Pia Renaudin, CEO of SciBase, expressed excitement about the study's milestone, highlighting its potential to improve patient well-being.
Importance 40 Sentiment 20
priv
Carnegie Investment Bank
Carnegie Investment Bank is mentioned as the Certified Advisor for SciBase, indicating its role in financial advisory but not directly in the study.
Importance 10 Sentiment 0
cnt
Sweden
Sweden is the location of the Karolinska Institute, where SciBase's technology originated, and Stockholm is where SciBase is based.
Importance 5 Sentiment 0
exch
Nasdaq First North Premier Growth Market
SciBase has been listed on the Nasdaq First North Premier Growth Market since June 2, 2015, providing a trading platform for its shares.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.